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Background: Recognition that ascending infection leads to preterm birth has led to a number of studies that have
evaluated the treatment of vaginal infections in pregnancy to reduce preterm birth rates. However, the role of
candidiasis is relatively unexplored. Our aim was to undertake a systematic review and meta-analysis to assess
whether treatment of pregnant women with vulvovaginal candidiasis reduces preterm birth rates and other adverse
birth outcomes.
Methods: We undertook a systematic review and meta-analysis of published randomised controlled trials (RCTs) in
which pregnant women were treated for vulvovaginal candidiasis (compared to placebo or no treatment) and
where preterm birth was reported as an outcome. Trials were identified by searching the Cochrane Central Register
of Controlled Trials, Medline and Embase databases to January 2014. Trial eligibility and outcomes were pre-specified.
Two reviewers independently assessed the studies against the agreed criteria and extracted relevant data using a
standard data extraction form. Meta-analysis was used to calculate pooled rate ratios (RR) and 95% confidence
intervals (CI) using a fixed-effects model.
Results: There were two eligible RCTs both among women with asymptomatic candidiasis, with a total of 685 women
randomised. Both trials compared treatment with usual care (no screening for, or treatment of, asymptomatic
candidiasis). Data from one trial involved a post-hoc subgroup analysis (n = 586) of a larger trial of treatment of 4,429
women with asymptomatic infections in pregnancy and the other was a pilot study (n = 99). There was a significant
reduction in spontaneous preterm births in treated compared with untreated women (meta-analysis RR = 0.36,
95% CI = 0.17 to 0.75). Other outcomes were reported by one or neither trial.
Conclusions: This systematic review found two trials comparing the treatment of asymptomatic vaginal candidiasis in
pregnancy for the outcome of preterm birth. Although the effect estimate suggests that treatment of asymptomatic
candidiasis may reduce the risk of preterm birth, the result needs to be interpreted with caution as the primary driver
for the pooled estimate comes from a post-hoc (unplanned) subgroup analysis. A prospective trial with sufficient power
to answer the clinical question ‘does treatment of asymptomatic candidiasis in early pregnancy prevent preterm
birth’ is warranted.
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Preterm birth is a major pregnancy complication affect-
ing 5% to 18% of births worldwide [1,2]. Infants born
preterm are at increased risk of death, significant neo-
natal complications, long-term adverse health outcomes
and developmental impairment [3-5].
Preterm birth (birth before 37 completed weeks of ges-
tation) results from either spontaneous onset of labour
(including preterm prelabour rupture of the membranes)
or a clinical decision that planned birth should occur
because of pregnancy complications. The cause of
spontaneous preterm birth is often unknown, but
intrauterine infection is implicated in up to 40%
[4,6,7]. The likely pathway to intrauterine infection is
ascending genital tract infection [6-9]. Genital tract in-
fection is more frequent among women with spontan-
eous preterm births at lower gestational ages [7,10].
Importantly, infection may occur before or early in
pregnancy, may be asymptomatic and may remain
undetected [7,11].
The role of infection in preterm birth is thought to
be a chronic process, with early pregnancy a period
of vulnerability to establishment of inflammatory re-
sponses that may be the trigger for preterm parturition
[6,9,11]. Organisms detected in the uterus before
membrane rupture are typically of low virulence, prob-
ably accounting for both the chronicity of intrauterine
infections and the frequent absence of overt clinical signs
of infection [6,8].
Pregnancy increases the frequency of vaginal Candida
colonization [12]. This is thought to be the consequence
of increased levels of circulating oestrogens and depos-
ition of glycogen and other substrates in the vagina dur-
ing pregnancy [12]. Candida colonisation may disrupt
normal vaginal flora so that there is a decrease in lacto-
bacilli and an increase in proinflammatory organisms
[9,13]. However, few studies have assessed the associa-
tions between candidiasis and preterm birth. A sys-
tematic review of treatment trials for symptomatic
candidiasis during pregnancy assessed ‘cure’ (negative
culture or symptom relief posttreatment) but not
pregnancy outcomes [14].
Studies utilising population-based data from Hungary
reported that vaginal clotrimazole treatment of candidia-
sis during pregnancy was associated with a 34% to 64%
reduction in the prevalence of preterm birth [15-17]. In
contrast, two cohort studies found no significant associ-
ation between preterm birth and moderate to heavy
growth of Candida species among women at 22 to
30 weeks gestation [18,19]. Therefore, our aim was to
undertake a systematic review and meta-analysis to
assess whether the treatment of pregnant women
with vulvovaginal candidiasis reduces preterm birth rates
and other adverse birth outcomes. The importance ofreducing preterm birth rates warranted performing a
meta-analysis of randomised clinical trials, which might
amass sufficient statistical power to provide clear evidence
about a possible protective effect.
Methods
Search strategy
The study procedure and outcomes were pre-specified
[20]. We identified relevant studies by searching the
Cochrane Central Register of Controlled Trials, Medline
and Embase from database inception through 31 January
2014. There were no language restrictions. The data-
base searches were supplemented by hand-searching
the reference lists of relevant reviews and potentially
eligible studies. Search terms (using keywords and
Medical Subject Headings (MeSH), all exploded) in-
cluded (‘candida’ or ‘candidiasis’ or ‘candidosis’ or
‘yeasts’) and (‘pregnancy’ or ‘preterm/premature birth’)
and ‘antifungal agents’. Conference and meeting abstracts
were not included, and no attempt was made to identify
unpublished studies or contact the authors of published
studies.
Eligibility criteria
Randomised controlled trials (RCT) in which pregnant
women were treated for symptomatic or asymptomatic
vulvovaginal candidiasis and where preterm birth was re-
ported as an outcome were the pre-specified eligibility cri-
teria [20]. Only RCTs that compared treatment (imidazoles
or other proven therapeutic agents) with placebo or
no intervention were of interest. Quasi-randomised
designs, such as alternate allocation or the use of med-
ical record numbers, were not eligible. Mycologically
confirmed diagnoses of vulvovaginal candidiasis (i.e. a
positive culture and/or microscopy for yeast) were
required.
Study selection
The titles and abstracts of all potential studies identified
for inclusion as a result of the search strategy were inde-
pendently assessed for inclusion by two reviewers. The
two reviewers also assessed the full papers of potentially
eligible studies or where eligibility was unclear. Discrep-
ancies at both stages of study selection were resolved
through discussion.
Risk of bias
The two review authors also independently assessed the
risk of bias (as low, high, or unclear) for each study
using the following pre-specified criteria: random se-
quence generation, allocation concealment, blinding of
participants and personnel, blinding of outcome assess-
ment and completeness of outcome data [20]. Again,
discrepancies were resolved through discussion.
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Preterm birth (<37 completed weeks of gestation) fol-
lowing spontaneous onset of labour or following preterm
prelabour rupture of membranes.
Secondary infant outcomes
1. Any birth before 37 weeks
2. Medically indicated birth (by labour induction or
prelabour caesarean section) before <37 weeks
3. Birth before 32 weeks
4. Birth weight less than the tenth percentile for
gestational age
5. Birth weight <2,500 g
6. Apgar score of less than 7 at 5 min
7. Respiratory distress syndrome
8. Use of mechanical ventilation
9. Duration of mechanical ventilation
10. Intraventricular haemorrhage
11. Retinopathy of prematurity
12. Chronic lung disease
13. Necrotising enterocolitis
14. Perinatal mortality (stillbirth or neonatal death)
15. Admission to neonatal intensive care unit
16. Neonatal length of hospital stay
17. Breastfeeding
Secondary maternal outcomes
1. Preterm prelabour rupture of the membranes
2. Spontaneous pregnancy loss <20 weeks gestation,
3. Mode of birth
4. Duration of maternal hospitalisation at the time
of birth
5. Maternal views/satisfaction with the therapy
6. Maternal anxiety
Data extraction
Data were extracted independently by the two reviewers,
and disagreements were resolved by discussion. A
standard data extraction form was used to extract
data on study characteristics, methods and study re-
sults. All data on study results were entered into an
Excel Spreadsheet.
Data synthesis
Characteristics, main findings and risk of bias assess-
ment were tabulated for each study. The raw data pre-
sented in the included studies were used to determine
the outcome rates for intervention and control groups of
each study. Where data were missing (incomplete
follow-up on all women), the results reported in the
studies as the numerator (no information on those lost
to follow-up) and denominator (all women randomised)were used; no imputation of outcomes was made. There
were two pre-specified subgroup analyses for the pri-
mary outcome: symptomatic and asymptomatic candid-
iasis, and commencing treatment before 20 weeks
gestation versus after 20 weeks gestation. For each di-
chotomous outcome of interest within individual studies,
relative risks (RR) and 95% confidence intervals (CIs)
were calculated according to the intention to treat. The
assumption of homogeneity of treatment effect between
studies was assessed using Cochran’s Q test statistic and
the I2 test. Meta-analysis was used to calculate pooled
risk ratios (RR) and 95% confidence intervals (CI) using
a fixed-effects model (Mantel-Haenszel), unless the as-
sumption of homogeneity was rejected (P < 0.1) when a
random effects model would be used. Statistical analyses
were performed using the ‘metan’ command in STATA




A total of 1,014 unique articles were identified (Figure 1).
Of these 17 underwent full review as potentially eligible
or where the eligibility was unclear from the title and
abstract [21-37]. Three papers compared treatment ver-
sus placebo or no intervention for pregnant women
with candidiasis [29,35,37] but only two had the out-
come of preterm birth and were eligible for inclusion
(Table 1) [29,35].
Characteristics of included studies
Both studies included women with asymptomatic vaginal
candidiasis and both compared treatment with clotrima-
zole to no treatment (Table 1) [29,35]. Spontaneous pre-
term birth was the primary outcome for both studies. As
spontaneous preterm birth was the only outcome avail-
able from both studies, none of the other planned meta-
analysis outcomes could be assessed. There were no
relevant studies assessing symptomatic candidiasis where
preterm birth was the outcome.
The aim of the study by Kiss and colleagues was to
assess whether general screening for, and treatment of,
asymptomatic vaginal infections (bacterial vaginosis,
candidiasis and/or trichomoniasis) was effective in redu-
cing the rate of preterm birth and late miscarriage [29].
Women who were culture positive for any of the three
conditions (n = 4,429) were randomised to treatment
(appropriate to the organism: clindamycin, clotrimazole
and/or metronidazole, respectively) or to usual care
(culture result not revealed and no treatment). There
was no pre-specified subgroup analysis by infection type
so the information on treatment of asymptomatic can-
didiasis from this trial was extracted from the published
paper post-hoc.
Figure 1 Summary of evidence search and selection.
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trial, Roberts and colleagues undertook a pilot study
with the specific aim of assessing treatment of asymp-
tomatic candidiasis to prevent preterm birth [35]. The
study design was essentially the same although the eligi-
bility criteria were limited to women with asymptomatic
candidiasis.
The asymptomatic Candida colonisation rate was
14.1% (15 to 19 weeks gestation) in the Kiss et al. study
and 19.6% (12 to 19 weeks gestation) in the Roberts
et al. study. Kiss et al. reported that women were to be
retested, and if necessary retreated, at 24 to 27 weeks.
However, overall, only 22% of women in the entire treat-
ment arm had a follow-up gram stain and of these 27%
still had a vaginal infection present, including 78 (27%)
with candidiasis, all of whom were retreated. Roberts
et al. report a posttreatment colonisation rate of 48% on
average 10 weeks after recruitment but asymptomatic
women were not offered further treatment.
Risk of bias
Both studies utilised computer random number gener-
ation and central randomisation procedures. In the Kiss
et al. study, women who were randomised to clotrima-
zole treatment (and their obstetricians) were not blinded
to their treatment allocation. However, the untreated
group (93% of women screened) included both women
without infections and those with asymptomatic infec-
tions who were randomised to usual care. Clinicians and
women were blinded to the colonisation-status withinthis group. Roberts et al. used a similar method but
women allocated to clotrimazole treatment were notified
and treated by the study personnel. So, although the
women in the treatment arm were not blinded, clinicians
were blinded to treatment allocation unless it was re-
vealed during the subsequent pregnancy management.
Like the Kiss et al. study, the untreated group (90% of
participants) included women with and without asymp-
tomatic candidiasis and the clinicians and women were
blinded to this information. This partial blinding of
participants and personnel to exposure status was con-
sidered unlikely to affect results. Furthermore, the as-
sessment of outcomes from medical records was blinded
and gestational age determination is not subjective
(based on ultrasound dating and date of birth). The can-
didiasis subgroup analysis in the Kiss et al. study was
not pre-specified but extracted post-hoc from the pub-
lished paper. Furthermore, Kiss et al. did not report loss
to follow-up and exclusions by treatment arm or infec-
tion subgroups so the number of women with candidia-
sis for whom outcome data were missing could not be
determined. However, overall 3.2% women were lost to
follow-up and there were 3.0% post-randomisation ex-
clusions (1.5% multiple pregnancies; 1.5% did not fulfil
the inclusion criteria). The follow-up rate was 99% in
the Roberts et al. study (outcome information was
missing for one woman) with no post-randomisation
exclusions.
For both studies, the risk of bias was considered low
for all aspects assessed: random sequence generation,
Table 1 Characteristics of randomised controlled trials assessing treatment of vaginal candidiasis to prevent preterm birth
Study Study period
and location
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personnel, blinding of outcome assessment and com-
pleteness of outcome data. However, neither study had a
published protocol so it is possible that there was select-
ive choice for reporting of secondary outcomes. Ac-
knowledged funding for the trials was from government
sources, and there is no suggestion (although not expli-
citly stated) that the trial treatment was provided by a
pharmaceutical company (Table 1).
Data synthesis
The only outcome available from both studies was spon-
taneous preterm birth. Meta-analysis showed an overall
reduction in spontaneous preterm birth (RR = 0.36, 95%
CI = 0.17 to 0.75) with similar point estimates from both
studies but little contribution (and very wide confidence
intervals) around the estimate from the pilot study by
Roberts et al. (Figure 2). While Roberts et al. reported
on subsequent pregnancy complications, labour induc-
tion, mode of delivery, birth weight and nursery admis-
sions, no other outcomes were available from the Kiss
trial.
Discussion
This systematic review found two trials comparing the
treatment of asymptomatic vaginal candidiasis in preg-
nancy with usual care (no screening and no treatment of
asymptomatic vaginal candidiasis) for the outcome of
preterm birth. The findings provide support for the hy-
pothesis that treatment of asymptomatic candidiasis may
reduce the risk of preterm birth. Although the two stud-
ies had similar methods, treatment regimens and find-
ings among general maternity populations in different
countries, the result needs to be interpreted with caution
as the primary driver for the pooled estimate is a post-
hoc subgroup analysis of the Kiss trial. We believe that
the meta-analysis result supports the need for a larger
trial that specifically addresses the question of whether
the treatment of asymptomatic candidiasis early inFigure 2 Meta-analysis of spontaneous preterm birth among womenpregnancy can reduce the risk of spontaneous preterm
birth. If a simple, inexpensive intervention is demon-
strated to reduce spontaneous preterm birth, this
would change current maternity care internationally.
A significant reduction in preterm birth would not
only reduce perinatal mortality and morbidity, but
also have major resource implications, such as re-
duced need for neonatal intensive care and childhood
hospitalisations.
The two trials reported different colonisation rates of
asymptomatic candidiasis (14.1% and 19.6%) [29,35].
This reflects population baseline characteristics and
slightly varying gestational age ranges for recruitment.
Other studies report colonisation rates that range from
14% to 38% for symptomatic candidiasis at 22 to 30
weeks gestation but do not report asymptomatic rates
[18,19,38]. Some of the population risk factors for can-
didiasis are also risk factors for preterm birth including
African-American women, low socioeconomic status,
smoking, maternal medical conditions and bacterial
vaginosis [16,18,29].
Both trials included in the meta-analysis used a similar
design, described by Roberts et al. as a Prospective,
Randomised, Open-label, Blinded-Endpoint (PROBE)
design. PROBE designs have been used in cardiovascular
disease trials [39-46], and the two trials in this review
may be the first obstetric trials to use this design. Fea-
tures include strict randomisation and allocation con-
cealment procedures, and blinding of those assessing the
trial endpoints [41]. The drug interventions are typically
commercially available as indicated in the Roberts trial
[35]. Consequently, as the treatment protocol adheres
closely to routine clinical practice, the results from a
PROBE design may be more generalisable to the prag-
matic management of patients than double-blind,
placebo-controlled trials [41,45]. A potential disadvan-
tage of a placebo-controlled trial for answering this
preterm birth prevention question is that a vaginally ad-
ministered placebo may be biologically active as it wouldwith asymptomatic candidiasis: clotrimazole versus usual care.
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an independent effect on vaginal flora [35].
Clotrimazole, the treatment used in both the included
studies, is classified as a category A drug meaning it has
been used by a large number of pregnant women and
women of childbearing age without any proven increase
in the frequency of malformations or other direct or in-
direct harmful effects on the fetus having been observed
[47]. Large population-based studies have not demon-
strated risks to the fetus following exposure to clotrima-
zole in pregnancy [48]. Randomised trials of treatment
of symptomatic candidiasis in pregnancy provide
evidence for the use of topical imidazoles (such as clotri-
mazole), rather than nystatin or hydrargaphen, for
successful eradication of Candida from the vagina. Fur-
thermore, the susceptibility of both Candida albicans
and non-albicans Candida vaginal isolates to azole anti-
fungal agents, such as clotrimazole, supports the contin-
ued practice of azole antifungal agents for empirical
therapy of Candida vaginitis [49].
Despite the interest in infection as a risk factor for
preterm birth, we found only two trials (including a
small pilot study) to contribute to this review. Perhaps
as Candida is considered a vaginal commensal organism
[13], the role of candidiasis in preterm birth has not
been pursued with the same attention as bacterial vagin-
osis and other vaginal organisms [11,50-53]. However, it
is also possible that some relevant studies that could
change the finding of the meta-analysis in the direction
of no association were missed as only controlled vocabu-
lary search terms were used and the search was limited
to published studies.
Rather than pregnancy outcomes, previous research
has mostly focussed on the question of best treatment
for eradicating Candida colonisation in pregnant women
with symptomatic candidiasis. The availability of only
two trials precludes the opportunity to explore issues
like heterogeneity and any impact of reporting biases in
sensitivity and subgroup analyses. Only one outcome
(spontaneous preterm birth) was available from both
studies, and future trials should consider other potential
pregnancy outcomes and treatment side effects [54].
Although we identified 11 treatment trials of symp-
tomatic candidiasis in pregnancy, all were published
before 1985, only one compared treatment to placebo
and none reported pregnancy outcomes, only the rate
of Candida eradication [25,36,37,55-62]. Furthermore,
the seven studies that reported gestational age at re-
cruitment all included women who were too ad-
vanced in pregnancy to have an impact on preterm
birth [25,36,37,56,58,60,62].
Inclusion in the meta-analysis of some women with
missing outcome information is unlikely to change the
conclusions. From the Kiss et al. trial, the extent ofmissing data on the outcome of preterm birth for
women with candidiasis could not be determined but
was approximately 3% among all women with asymp-
tomatic infections. One woman (of 99) in the Roberts
et al. trial was missing information on birth outcome.
Only Roberts et al. reported other birth outcomes for
the treated and untreated groups of women but this
was limited by small event numbers: any preterm
birth (RR = 0.65; 95% CI = 0.11 to 3.74), spontaneous
vaginal birth (RR = 1.03; 95% CI = 0.64 to 1.64), in-
strumental vaginal birth (RR = 0.88; 95% CI = 0.39 to
1.98), caesarean section (RR = 1.09; 95% CI = 0.66 to
1.80), birth weight <2,500 g (RR = 0.98; 95% CI = 0.14
to 6.68) and nursery admission (RR = 1.31; 95% CI = 0.31
to 5.54). The remaining pre-specified outcomes were not
reported in either of the included studies.
The rationale of the two included trials is that early
treatment of vaginal infections is necessary for effective
prevention of infection-related preterm birth, as early
pregnancy is the period of greatest risk for the establish-
ment of inflammatory responses to low virulence organ-
isms that increase the risk of preterm birth [6-9].
Treatment later in pregnancy may have limited effect in
preventing preterm parturition if the inflammatory
responses are not fully reversible [4]. Importantly,
treatment does not necessarily eradicate Candida in
all women nor prevent recolonisation. Posttreatment
‘Candida eradication rates’ (assessed at 3 to 6 weeks) for
symptomatic candidiasis in pregnancy range from 69% to
100% (five trials, median 88%) [14] and for asymptomatic
candidiasis was 73% (assessed at 4 to 5 weeks) in the Kiss
trial [29] and 52% (assessed at 10 weeks) in the Roberts
trial [35]. However, it is not clear whether posttreat-
ment colonisation represents persistent colonisation or
recolonisation.
Conclusion
The findings of this review, that treating asymptomatic
candidiasis in early pregnancy may reduce spontaneous
preterm birth rates, need to be interpreted with caution.
The findings are based on only two published trials (a
pilot study and a post-hoc subgroup analysis with data
from 685 women who had 34 spontaneous preterm
births) both using clotrimazole and both in asymptom-
atic women, and the post-hoc subgroup analysis was the
primary driver for the pooled estimate. Furthermore,
there were insufficient data on other important infant
and maternal outcomes. This systematic review suggests
that a trial with sufficient power to answer the clinical
question ‘does treatment of asymptomatic candidiasis in
early pregnancy prevent preterm birth’ is warranted.
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